Dexlansoprazole information

Dexlansoprazole
Clinical data
Trade names	Kapidex, Dexilant, others
AHFS/Drugs.com	Monograph
MedlinePlus	a695020
License data	US DailyMed: Dexlansoprazole;
Routes of; administration	By mouth
Drug class	Proton pump inhibitor
ATC code	A02BC06 (WHO) ;
Legal status
Legal status	US: WARNINGRx-only;
Pharmacokinetic data
Excretion	50% renal and 47% in the feces
Identifiers
	IUPAC name (R)-(+)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole;
CAS Number	138530-94-6 ;
PubChem CID	9578005;
IUPHAR/BPS	5487;
ChemSpider	7852369 ;
UNII	UYE4T5I70X;
KEGG	D08903 ;
ChEMBL	ChEMBL1201863 ;
ECHA InfoCard	100.215.667
Chemical and physical data
Formula	C16H14F3N3O2S
Molar mass	369.36 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES n1c2ccccc2[nH]c1[S@](=O)Cc3nccc(c3C)OCC(F)(F)F;
	InChI InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1 ; Key:MJIHNNLFOKEZEW-RUZDIDTESA-N ;
	(what is this?) (verify)

Dexlansoprazole, is a medication which reduces stomach acid.^[3] It is used to treat gastroesophageal reflux disease.^[3] Effectiveness is similar to other proton pump inhibitors (PPIs).^[4] It is taken by mouth.^[3]

Common side effects include diarrhea, abdominal pain, and nausea.^[3] Serious side effects may include osteoporosis, low blood magnesium, Clostridium difficile infection, anaphylaxis, and pneumonia.^[3] Use in pregnancy and breastfeeding is of unclear safety.^[5] It works by blocking H⁺/K⁺-ATPase in the parietal cells of the stomach.^[3]

Dexlansoprazole was approved for medical use in the United States in 2009.^[3] In Canada in 2016, it was the most expensive PPI available.^[4] In 2020, it was the 263rd most commonly prescribed medication in the United States, with more than 1 million prescriptions.^[6]^[7]

^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^ Product Information: DEXILANT delayed release oral capsules, dexlansoprazole delayed release oral capsules. Takeda Pharmaceuticals, Inc., Deerfield, IL, 2010. Revised: September 2012
^ ^a ^b ^c ^d ^e ^f ^g "Dexlansoprazole Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
^ ^a ^b "[99] Comparative effectiveness of proton pump inhibitors | Therapeutics Initiative". 28 June 2016. Retrieved 14 July 2016.
^ "Dexlansoprazole Use During Pregnancy". Drugs.com. Retrieved 3 March 2019.
^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
^ "Dexlansoprazole - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.

[FDA-AllBoxedWarnings-1] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

[Label-2] Product Information: DEXILANT delayed release oral capsules, dexlansoprazole delayed release oral capsules. Takeda Pharmaceuticals, Inc., Deerfield, IL, 2010. Revised: September 2012

[AHFS2019-3] ^ ^a ^b ^c ^d ^e ^f ^g "Dexlansoprazole Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.

[TI2016-4] "[99] Comparative effectiveness of proton pump inhibitors | Therapeutics Initiative". 28 June 2016. Retrieved 14 July 2016.

[Preg2019-5] "Dexlansoprazole Use During Pregnancy". Drugs.com. Retrieved 3 March 2019.

[6] "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.

[7] "Dexlansoprazole - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.

Dexlansoprazole information

and 10 Related for: Dexlansoprazole information

Dexlansoprazole

Lansoprazole

Discovery and development of proton pump inhibitors

Rabeprazole

Benzimidazole

Laryngospasm

ATC code A02

List of largest selling pharmaceutical products

C16H14F3N3O2S

Acid peptic diseases